SEVEFAST 400 TAB
MRP: 2
Packaging: 10x10
Pack Type: tablet
Composition:
Sevelamer Carbonate 400 mg
Indication:
Used to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Helps prevent complications of hyperphosphatemia, such as bone disorders and cardiovascular issues.
Description:
Sevelamer Carbonate is a non-calcium, non-metallic phosphate binder used primarily to control hyperphosphatemia (high phosphate levels) in patients with chronic kidney disease (CKD) on dialysis. By binding dietary phosphate in the gastrointestinal tract, it reduces phosphate absorption, thereby helping to maintain balanced serum phosphate levels and prevent complications such as vascular calcification and bone disease.
The 400 mg tablet formulation provides an effective dose for phosphate binding with fewer side effects related to calcium overload.
Tags:
- Controls hyperphosphatemia in CKD patients on dialysis
- Reduces phosphate absorption from diet
- Non-calcium-based, lowering risk of hypercalcemia
- Helps prevent vascular calcification and bone disorders
- Well tolerated with minimal systemic absorption
Usage Information
Dosage
Typical dose: 800 mg to 1600 mg (2 to 4 tablets) taken with meals Tablets should be swallowed whole with water Dosage adjusted based on serum phosphate levels and clinical response Continuous treatment during dialysis recommended
Side Effects
Gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal pain Dyspepsia Rare: Intestinal obstruction or impaction with prolonged use Possible changes in vitamin D and calcium levels—monitor regularly
Contraindications
Known hypersensitivity to Sevelamer or its components Bowel obstruction or ileus Use caution in patients with severe gastrointestinal motility disorders